U of M ILD

The University of Michigan Interstitial Lung Disease Program is committed to outstanding care and research in ILDs.

[IPF Today @TodayIpf]

Ofev now approved for all progressing fibrotic interstitial lung diseases #ILD #IPF
https://t.co/sTssFeuofU

[U of M ILD @MichiganILD]

@dreamboat1317 @accpchest @atscommunity DM me...lets chat!

[Dr. Dinesh Khanna @sclerodermaUM]

David Roofeh presenting his NIH T32 project to external advisors. Supported by @MichiganILD @ellakaz @UMIntMed and all the experts around the globe who have supported him

[Leticia Kawano-Dourado (I'm on BlueSky/LinkedIn) @leticiakawano]

#MILD2019

[Gisli Jenkins @IPFdoc]

#MILD2019 despite the floods a full house for an exciting day talking about trying to #CureIPF. @lungDrE @LouiseVwain @bedoctored @gburgeILDNN @leticiakawano where’s @KaminskiMed?

[U of M ILD @MichiganILD]

Hopping into a cab to the hotel. My #planestrainsandautomobiles journey is almost over!

[U of M ILD @MichiganILD]

On the train from #London to #Nottingham! What a lovely way to travel!

[U of M ILD @MichiganILD]

Just landed in London on my way to Nottingham for #MILD Fibrosis meeting with @leticiakawano @IPFdoc @lungDrE

[U of M ILD @MichiganILD]

@EBRheum @leticiakawano @sclerodermaUM @DrPujaMehta1 @TobyMMaher @RheumILD @UMIntMed Potential harm is what patients MAY experience on a medication. It is not a guarantee of an adverse effect. And yes, an RCT. But there’s a difference between a drug effect and a synergy between 2 drugs to cause an effect.

[U of M ILD @MichiganILD]

@EBRheum @leticiakawano @sclerodermaUM @DrPujaMehta1 @TobyMMaher @RheumILD @UMIntMed That’s “potential harm” in numbers similar to the INPULSIS trials. We’re also unable to determine how much of those adverse effects are from the MMF as well, So you weigh risks and benefits. Many IPF patients on nintedanib and pirfenidone tolerate them enough to continue.

[U of M ILD @MichiganILD]

@EBRheum @leticiakawano @sclerodermaUM @DrPujaMehta1 @TobyMMaher @RheumILD @UMIntMed You could also argue that there was a small benefit, and certainly no harm, in patients on background MMF receiving nintedanib. Denying patients a medication that *might* work is also reasonable.

[U of M ILD @MichiganILD]

@EBRheum @sclerodermaUM @DrPujaMehta1 @TobyMMaher @leticiakawano @RheumILD @UMIntMed Agreed. We will be discussing in our own program to define an algorithm. Will post when we’ve decided.

[Dr. Dinesh Khanna @sclerodermaUM]

Great work and congrats on the presentation!@UMIntMed

[U of M ILD @MichiganILD]

@leticiakawano @MariPiervalerio @sclerodermaUM @RheumILD Will take a 280-character stab at this. No “proof” that IPAF is a separate disease. HOWEVER, only 16% went on to develop a CTD-ILD, and the survival clearly differs from IPF, even when the pattern on CT or biopsy is UIP. Argues that maybe there is a separate clinical condition?

[Pier-Valerio Mari @MariPiervalerio]

#ERS2019
#ILD
#IPAF

My #2 e-poster, IPAF (of course).

Are you sure that IPAF is another, confusing, research term? Is it a clinical entity? Is a different subgroup of other ILDs such as IPF?

If you really want to pull my legs, take a look at the poster!

[U of M ILD @MichiganILD]

@RajaniSurendarB Apologies but @MichiganILD , along with Elvis, will have left the building!

[NEJM @NEJM]

Patients w/ a progressive interstitial lung disease, 62% of whom had a CT pattern of usual interstitial pneumonia, treated with nintedanib had a lower rate of loss of forced vital capacity than those given placebo. See the INBUILD trial. #ERSCongress https://t.co/PtU6HuZVQs

[U of M ILD @MichiganILD]

@leticiakawano second half of #ILD session at #ERS2019 - #nomoremanels

[U of M ILD @MichiganILD]

3/ Dr. Troy: SLB only adds 1 confident diagnosis in 10 patients compared to cryobiopsy.

[U of M ILD @MichiganILD]

1/ Dr. Lauren Troy brings the controversy in the last talk #COLDICE now published in @LancetRespirMed

[U of M ILD @MichiganILD]

2/ Nice agreement among pathologists between SLB or cryobiopsy for UIP or probable UIP, but actual diagnoses were less